{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:41:32Z","timestamp":1790484092924,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cmi.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:55:36Z","timestamp":1553712936000},"page":"818-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia"],"prefix":"10.1016","volume":"25","author":[{"given":"S.","family":"Weis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kesselmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scherag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.03.010_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.03.010_bib2","series-title":"Mikrobiologisch-infektiologische Qualit\u00e4tsstandards (MiQ)","article-title":"Blutkulturdiagnostik: Sepsis, Endokarditis, Katheterinfektionen","author":"Seifert","year":"2007"},{"key":"10.1016\/j.cmi.2019.03.010_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","article-title":"International bacteremia surveillance collaborative, The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.010_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.cmi.2019.03.010_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/cit499","article-title":"Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia","volume":"57","author":"Lopez-Cortes","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cmi.2016.11.014","article-title":"Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review","volume":"23","author":"Loubet","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.010_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.1892","article-title":"Beta-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins","volume":"37","author":"Li","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.03.010_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2018.02.013","article-title":"A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia","volume":"52","author":"Davis","year":"2018","journal-title":"Int J Anitmicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.010_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Korea, Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.010_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/11.3.361","article-title":"Noculum effect","volume":"11","author":"Brook","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2019.03.010_bib12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and beta-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Res"},{"key":"10.1016\/j.cmi.2019.03.010_bib13","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib14","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/jac\/dkt254","article-title":"Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals","volume":"68","author":"Rincon","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","article-title":"Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome","volume":"34","author":"Chong","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jiac.2017.10.021","article-title":"Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other beta-lactams","volume":"24","author":"Saeki","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib17","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib18","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2008"},{"key":"10.1016\/j.cmi.2019.03.010_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2019.03.010_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2019.03.010_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","article-title":"Estimation of a common effect parameter from sparse follow-up data","volume":"41","author":"Greenland","year":"1985","journal-title":"Biometrics"},{"key":"10.1016\/j.cmi.2019.03.010_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2307\/2531052","article-title":"Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models","volume":"42","author":"Robins","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.cmi.2019.03.010_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trial"},{"key":"10.1016\/j.cmi.2019.03.010_bib24","unstructured":"G.S. Higgins JPT, (Ed), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane collaboration, Available from: http:\/\/www.cochrane-handbook.org."},{"key":"10.1016\/j.cmi.2019.03.010_bib25","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"RCoreTeam","year":"2017"},{"key":"10.1016\/j.cmi.2019.03.010_bib26","first-page":"40","article-title":"Meta: An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"10.1016\/j.cmi.2019.03.010_bib27","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1055\/a-0816-9947","article-title":"Infektiologische Konsile bei Patienten mit Staphylococcus aureus Bakteri\u00e4mie \u2013 eine retrospektive Beobachtungsstudie am Universit\u00e4tsklinikum Jena","volume":"143","author":"Kimmig","year":"2018","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.cmi.2019.03.010_bib28","first-page":"1451","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"60","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib29","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2018.02.004","article-title":"Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","author":"Monogue","year":"2018","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.cmi.2019.03.010_bib31","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.010_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1542-4758.2010.00507.x","article-title":"High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia","volume":"15","author":"Renaud","year":"2011","journal-title":"Hemodial Int"},{"key":"10.1016\/j.cmi.2019.03.010_bib34","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib35","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","article-title":"Risk factors for idiosyncratic drug-induced liver injury","volume":"138","author":"Chalasani","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2019.03.010_bib36","doi-asserted-by":"crossref","first-page":"e01816","DOI":"10.1128\/AAC.01816-17","article-title":"Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin","volume":"62","author":"Eljaaly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib37","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.010_bib38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/bcp.13554","article-title":"Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia","volume":"84","author":"Rindone","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2019.03.010_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative Evaluation of the Tolerability of Cefazolin and Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections in the Outpatient Setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.diagmicrobio.2004.07.006","article-title":"The inoculum effect: fact or artifact?","volume":"50","author":"Craig","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2019.03.010_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2019.03.010_bib44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.010_bib45","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.04677-14","article-title":"Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"59","author":"Rao","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:55Z","timestamp":1761117715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19301120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1198743X19301120"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.010","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}